Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 8/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PTGFR | P43088 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723215 | 0.92 | HPGD (0.41) | DDR1TACR1TP53MAPTKDM4E | |
| SCHEMBL1721890 | 0.91 | KMT2A (0.46) | DDR1TACR1MAPTKDM4EALDH1A1 | |
| SCHEMBL1721590 | 0.90 | TP53 (0.49) | DDR1TP53MAPTALDH1A1HPGD | |
| SCHEMBL1721456 | 0.89 | CSNK1D (0.44) | DDR1TP53MAPTKDM4EALDH1A1 | |
| SCHEMBL1722065 | 0.88 | TACR1 (0.48) | TACR1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1722399 | 0.86 | DDR1 (0.41) | DDR1TACR1MAPTKDM4EALDH1A1 | |
| SCHEMBL1721222 | 0.86 | SORT1 (0.43) | TACR1KDM4EL3MBTL1 | |
| SCHEMBL1722435 | 0.85 | MLYCD (0.48) | TACR1HPGDMEN1KMT2A | |
| SCHEMBL1721202 | 0.85 | MTOR (0.43) | TACR1KDM4EL3MBTL1 | |
| SCHEMBL1721313 | 0.85 | SORT1 (0.51) | MAPTKDM4EALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2406229-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102811-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102811-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNJ2 | DDR1 4082/4885TACR1 2800/4885TP53 4800/4885 |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNJ2 | DDR1 4082/4885TACR1 2800/4885TP53 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.